EYPTA close call with a plot twist
EyePoint Pharmaceuticals dropped topline data from LUGANO, the first of two pivotal Phase 3 trials for DURAVYU 2.7mg in wet AMD, and the headline is basically: the drug got to the finish line, but not without tripping over a weird statistical banana peel.
The company says DURAVYU was non-inferior to on-label aflibercept in an ad hoc analysis after excluding a 4% asymmetric cohort — 9 of 211 patients — who had vision loss unrelated to wet AMD. But in the full dataset, the primary endpoint didn’t land. That’s the kind of result that can make biotech investors squint at the fine print like it’s a restaurant bill after too many appetizers.
Why Wall Street will still care
Even with the miss in the full population, EyePoint is leaning hard on the parts of the readout that still looked good:
- a 42% reduction in treatment burden versus aflibercept
- strong secondary endpoints
- supplement-free rates that support the convenience pitch
- a favorable safety profile with redosing
- solid anatomic control through Week 56
That matters because wet AMD is one of those chronic, repeat-visit diseases where fewer shots and less hassle can be a real selling point. If DURAVYU can genuinely reduce treatment burden without sacrificing efficacy, that’s the kind of story that can move from “interesting” to “commercially annoying for competitors.”
The investor takeaway
This is still a mixed bag, not a clean victory lap. Biotech reads rarely come with confetti, and this one is no exception. But the data were good enough to keep the program alive in the eyes of bulls who are willing to bet the subgroup issue was the main thing dragging the headline result down.
Big picture: EyePoint just gave investors a reason to keep watching DURAVYU instead of filing it under “nice try.” The next phase of the story is whether the second pivotal trial can turn this into a real approval shot.